We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $30.4 · 5 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Kyverna Therapeutics (KYTX) director granted RSUs and options vesting in 2027 - Stock Titan
Kyverna Therapeutics (KYTX) director granted RSUs and options vesting in 2027 Stock Titan
Kyverna Therapeutics (KYTX) director receives new RSU and option awards - Stock Titan
Kyverna Therapeutics (KYTX) director receives new RSU and option awards Stock Titan
Kyverna (NASDAQ: KYTX) director granted RSUs and stock options in new Form 4 - Stock Titan
Kyverna (NASDAQ: KYTX) director granted RSUs and stock options in new Form 4 Stock Titan
Kyverna Therapeutics (KYTX) chair has shares withheld for RSU taxes - Stock Titan
Kyverna Therapeutics (KYTX) chair has shares withheld for RSU taxes Stock Titan
Director Aktar Mert receives Kyverna (KYTX) RSU and stock option awards - Stock Titan
Director Aktar Mert receives Kyverna (KYTX) RSU and stock option awards Stock Titan
Kyverna Therapeutics Names Greg Martini CFO
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 12. | After market close (AMC) | $-0.68 | — | — | $0 | — | Scheduled |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 15. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2026. 05. 14. | JP Morgan | — | Maintain | Overweight → Overweight | — | JP Morgan: Overweight |
Compare a firm's past rating changes and its actions on other stocks in the same sector.
As of FY2026Q1 · Source: SEC/DART + price data
Filings, earnings, and institutional changes summarized in one paragraph, with source links.
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 205,267 | $1.93B | 0.00% | — | New position |
| 2 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 222,929 | $1.92B | 0.00% | — | New position |
See new positions, full exits, and weight changes.